98%
921
2 minutes
20
A series of 1,3,5-substituted indole derivatives was prepared to explore the anti-proliferative activity against a panel of human tumour cell lines. A 5-carboxamide derivative (27) emerged as the most potent compound of this series, inhibiting the HeLa cell growth at sub-micromolar concentrations. Target fishing of 27 using a combination of inverse virtual screening (IVS) approach and ligand-based shape similarity study identified the top-ranked targets for 27 as belonging to kinome. These results were further confirmed by in vitro binding assays, leading to the identification of 27 as multi-target kinase inhibitor. The compound 27 was further characterized for its antiproliferative activity by in cell studies, showing a mechanism of action involving modification of the cell cycle, increase in ROS release and caspase 3-expression and decrease in ERK expression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejmech.2019.01.066 | DOI Listing |
Anal Methods
September 2025
Department of Pharmacy, Kunshan Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, 215332, China.
(GR) is primarily produced in Laiyang and Chifeng. It is a functional food with therapeutic and health-promoting effects due to its antioxidant and anti-inflammatory properties. However, the current standards only stipulate authentication criteria, without establishing a comprehensive evaluation framework to systematically enhance the quality control of GR.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Epigallocatechin-3-gallate (EGCG), the predominant bioactive compound in green tea, has shown promise in lung cancer treatment; however, its molecular targets and antitumor mechanisms remain unclear. In this study, the therapeutic potential of EGCG against non-small cell lung (NSCLC) was evaluated, core targets were prioritized via network pharmacology, and molecular docking were employed to decipher the potential mechanism of action. Using bioinformatics, molecular docking, and functional enrichment analyses, 224 NSCLC-related targets were identified, with TP53, STAT3, AKT1, IL6, HSP90AA1, and JUN emerging as central hubs.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Colorectal Surgery, The Affiliated Xuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Objective: To investigate the anticancer effects and underlying mechanisms of 8-nitrotryptanthrin (8-Nitrotryp) against colorectal cancer (CRC).
Methods: The effects of 8-Nitrotryp on proliferation, colony formation, and migration were evaluated in HCT116 and SW480 cells, with comparisons to its parent compound tryptanthrin (Tryp). Mitochondrial membrane potential (MMP) was assessed using JC-1 staining, and early apoptosis was analyzed by flow cytometry.
Bioorg Chem
September 2025
Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:
RET tyrosine kinase, a key regulator of cellular signaling, is abnormally activated due to mutations or fusions in various cancers, making it an important therapeutic target. Traditional multi-kinase inhibitors (MKIs, such as cabozantinib and vandetanib) exhibit significant side effects due to non-selective inhibition of targets like VEGFR, and also suffer from resistance associated with RET mutations (e.g.
View Article and Find Full Text PDFBioorg Chem
September 2025
Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
Multi-targeted agents can sequentially act on two or more targets, leading to synergistic and more effective therapeutic effects against several complicated disorders, containing cancer, even with relatively modest action. The TRKs (tropomyosin receptor kinases) are confirmed as promising targets in anti-tumor drug discovery. Over the past 20 years, many small molecules TRK inhibitors have been identified, that some of them are being investigated in various clinical phases.
View Article and Find Full Text PDF